Abstract
Executive Summary
In this triple analysis report BioSeeker Group has analyzed three major and
intertwined areas of cancer R&D, Apoptopic agents, Antibodies and Vaccines in
Oncology, which are all subjects to an extensive number of innovative drug
candidates. This extensive 350+ pages report compiles and analyzes in parallel
the progress concerning drug development and competitive situation in the
three mentioned key oncology areas. The report will not only provide a
framework but also a careful identification and evaluation of drug candidates,
technologies and competitors.
There are today over 190 apoptopic drugs in active development for the
treatment of more than 40 different cancer indications. The top five pursued
cancer indications are: breast cancer, leukemia, lung cancer, lymphoma and
prostate cancer. A thorough target analysis of drugs in development reveals
more than 130 candidate targets for triggering apoptosis in cancer cells.
Competitive forces are reviewed, showing market leaders, active players and
changes in the competitive landscape. There are only one big pharma company
represented among the top 10 players in apoptopic drug development in
oncology. The acquisition of Idun Pharmaceutical in 2005 by Pfizer is
principal example of a further step in big pharma strategy to augment their
internal research and development efforts with high-potential, externally
sourced product candidates and technologies.
Apoptopic Agents Highlights
- In-depth competitive landscape assessment of the apoptopic market in
oncology
- Thorough review of utilized targets in apoptopic drug development
- Thorough review of approved drugs
- Progress analysis of five major cancer indications, including players,
drugs, clinical progress and pitfalls
Among the targeted therapies for cancer, immunotherapy is probably the most
versatile treatment strategy for the eradication of tumors, metastatic spread
or not. Main strategies of cancer immunotherapy aim at exploiting the
therapeutic potential of tumor-specific antibodies and cellular immune
effector mechanisms (vaccines).
Immunotherapy in Highlights
- In-depth competitive landscape assessment of the cancer immunotherapy
market place; Including more than 200 immunotherapy drugs and pharmaceutical
companies
- Thorough review of tumor antigen discovery, immunomodulating strategies
and adjuvants
- Thorough review of antibody and vaccine delivery and technologies
surrounding it - The next generation
- Progress analysis of six major cancer vaccine indications and late stage
antibody development projects, including players, drugs, clinical progress and
pitfalls
View Cart
